Objective To explore explore the effects of urapidil combined with benazepril on N-terminal proBNP and cardiac function in patients with coronary heart disease complicated with heart failure.Methods A total of 118 patients with coronary heart disease and heart failure admitted to Zhejiang Youth Hospital from September 2021 to September 2023 were selected as the study subjects.With a method of random number table,they were randomly divided into a control group(treated with benazepril)and an observation group(treated with benazepril and urapidil)with 59 patients in each group.Compare the clinical efficacy,cardiac function,inflammatory cytokines,and NT-proBNP levels between the two groups and observe the occurrence of adverse reactions.Results The total clinical effective rate of the observation group(90%)is higher than that of the control group(73%)(χ2=5.587,P<0.05).After 2 weeks of treatment,the left ventricular ejection fraction(LVEF)and cardiac output(CO)[(49.7±3.2)%,(5.2±0.4)L/min]in the observation group were higher than those in the control group[(47.9±3.8)%,(4.9±0.5)L/min],and the left ventricular end systolic diameter(LVESD)(36.0±3.0)mm was shorter than that in the control group(39.8±3.2)mm(t=2.824,P=0.006;t=3.009,P=0.002;t=6.651,P<0.01).After 2 weeks of treatment,the levels of high-sensitivity C-reactive protein(hs-CRP)and NT-proBNP in the observation group[(6.5±1.3)mg/L,(796±23)pg/ml]were significantly lower than those in the control group[(8.0±1.5)mg/L,(1 490±219)pg/ml](t=5.639,P<0.01;t=24.231,P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(8%vs.5%)(χ2=0.536,P=0.464).Conclusion The combination treatment of urapidil and benazepril in patients with coronary heart disease and heart failure can effectively reduce the levels of-NT-proBNP and inflammation,improve their cardiac function and safety.
NETL
NSTL
万方数据
